We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

77 hedge funds and large institutions have $102M invested in Karyopharm Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

85% more call options, than puts

Call options by funds: $31.3M | Put options by funds: $16.9M

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

47% more capital invested

Capital invested by funds: $69.6M → $102M (+$32.6M)

43.31% more ownership

Funds ownership: 55.52% → 98.83% (+43%)

12% more funds holding

Funds holding: 69 → 77 (+8)

Holders
77
Holders Change
+8
Holders Change %
+11.59%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
32
Reduced
9
Closed
15
Calls
$31.3M
Puts
$16.9M
Net Calls
+$14.4M
Net Calls Change
+$14.3M

Top Buyers

1
CC
Commodore Capital
New York
+$14.9M
2
RCM
RA Capital Management
Massachusetts
+$14.6M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.6M
4
Goldman Sachs
Goldman Sachs
New York
+$7.22M
5
APM
Avidity Partners Management
Texas
+$6.04M

Top Sellers

1
OM
Opaleye Management
Massachusetts
-$6.84M
2
AAA
Affinity Asset Advisors
New York
-$2.97M
3
B
Braidwell
Connecticut
-$2.23M
4
EAM
Exome Asset Management
New York
-$2.18M
5
Ameriprise
Ameriprise
Minnesota
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
WBC
76
West Branch Capital
Massachusetts
$17 – – –
PF
77
PlanVest Financial
Maryland
$6 +$8 +1 New
OM
78
Opaleye Management
Massachusetts
– -$6.84M -930,000 Closed
B
79
Braidwell
Connecticut
– -$2.23M -303,370 Closed
EAM
80
Exome Asset Management
New York
– -$2.18M -295,541 Closed
Ameriprise
81
Ameriprise
Minnesota
– -$2.04M -276,881 Closed
Walleye Capital
82
Walleye Capital
New York
– -$704K -95,672 Closed
Two Sigma Advisers
83
Two Sigma Advisers
New York
– -$660K -89,729 Closed
CCM
84
Context Capital Management
California
– -$464K -62,995 Closed
QC
85
Quadrature Capital
United Kingdom
– -$439K -59,708 Closed
Simplex Trading
86
Simplex Trading
Illinois
– -$251K -32,868 Closed
Citadel Advisors
87
Citadel Advisors
Florida
– -$242K -31,709 Closed
PCM
88
Prelude Capital Management
New York
– -$211K -28,723 Closed
PAP
89
Persistent Asset Partners
Hong Kong
– -$140K -18,316 Closed
Tudor Investment Corp
90
Tudor Investment Corp
Connecticut
– -$95.1K -12,922 Closed
Corient Private Wealth
91
Corient Private Wealth
Florida
– -$10K -10,039 Closed
AP
92
Aspect Partners
Virginia
– -$2.88K -391 Closed
1 2 3
4

KPTI Hedge Fund Activity: Q1 2026 in Review

77 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2026, worth a combined $102M — up 47% from $69.6M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KPTI positions and 15 closed out — a net gain of 10 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was Commodore Capital, opening a new position worth an estimated $14.9M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.84M sold.

  • 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2026, up from 69 in Q4 2025.
  • Funds reported $102M of Karyopharm Therapeutics stock for Q1 2026, up 47% quarter-over-quarter.
  • 25 funds opened new Karyopharm Therapeutics positions in Q1 2026 and 15 closed out, a net change of +10 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2026 was Commodore Capital, an estimated $14.9M added.
  • The largest Karyopharm Therapeutics seller in Q1 2026 was Opaleye Management, an estimated $6.84M sold.

Based on aggregated 13F filings for Q1 2026.